Volume 9 Supplement 2
Mechanistic insights into non-immunosuppressive immunophilin ligands as potential antimalarial therapeutics
© Yoon et al; licensee BioMed Central Ltd. 2010
Published: 20 October 2010
Our structure-guided drug screening efforts resulted in an identification of novel adamantanyl-based-antimalarial compound named Supradamal (SRA). SRA exhibits a nanomolar inhibitory activity in both peptidylprolyl cis-trans isomerase (PPIase) assay and growth of P. falciparum cultured in human erythrocytes. In particular, SRA appears to inhibit the trophozoite development.
- Alag A, Qureshi IA, Bharatham N, Shin J, Lescar J, Yoon HS: NMR and crystallographic structures of the FK506 binding domain of human malarial parasite Plasmodium vivax FKBP35. Protein Sci. 2010,Google Scholar
- Kotaka M, Ye H, Alag R, Hu G, Bozdech Z, Preiser PR, Yoon HS, Lescar J: Crystal structure of the FK506 binding domain of Plasmodium falciparum FKBP35 in complex with FK506. Biochemistry. 2008, 47: 5951-61. 10.1021/bi800004u.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.